FILING ANALYSIS · MONDAY, NOVEMBER 16

InMed Pharmaceuticals Inc. MTRI — 8-K: Completion of Acquisition or Disposition of Assets

negative

Mentari Therapeutics' financials show significant operating expenses and net loss, with $62.0 million in total operating expenses and a net loss of $62.996 million for the nine months ended September 30, 2026. The company's cash and cash equivalents decreased to $45.791 million as of September 30, 2026, from $46.259 million as of December 31, 2025.

The filing

8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+